Native and oxidized low-density lipoproteins modulate the vasoactive actions of soluble β-amyloid peptides in rat aorta

Clinical Science

Volumn 113, Issue 11-12, 2007, Pages 427-434

  Smith, Christopher C T ^a   Stanyer, Lee ^a   Betteridge, D John ^a   Cooper, Michael B ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

amyloid; Alzheimer's disease; Aortic ring; Hypercholesterolaemia; Low density lipoprotein (LDL); Vasoconstriction; Vasorelaxation

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; LOW DENSITY LIPOPROTEIN; NORADRENALIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; VASCULAR RING; VASOCONSTRICTION; VASODILATATION;

ACETYLCHOLINE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; AORTA; DRUG SYNERGISM; LIPOPROTEINS, LDL; MALE; NOREPINEPHRINE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE CULTURE TECHNIQUES; VASOCONSTRICTION; VASODILATION;

EID: 36848999785     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20070082     Document Type: Article

References (29)

1. Hardy, J. and Alsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383-388
2. Scheuner, G., Eckman, C., Jensen, M. et al. (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864-870
3. Seubert, P., Vigo-Pelfrey, C., Esch, F. et al. (1992) Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 359, 325-327
4. Chen, M., Inestrosa, N. C., Ross, G. S. and Fernandez, H. L. (1995) Platelets are the primary source of amyloid β-peptide in human blood. Biochem. Biophys. Res. Commun. 213, 96-103
5. Li, Q.-X., Whyte, S., Tanner, J. E., Evin, G., Beyreuther, K. and Masters, C. L. (1998) Secretion of Alzheimer's disease Aβ amyloid peptide by activated human platelets. Lab. Invest. 78, 461-469
6. Smith, C. C. T. (1997) Stimulated release of the β-amyloid protein of Alzheimer's disease by normal human platelets. Neurosci. Lett. 235, 157-159
7. Smith, C. C. T., Hyatt, P. J., Stanyer, L. and Betteridge, D. J. (2001) Platelet secretion of β-amyloid is increased in hypercholesterolaemia. Brain Res. 896, 161-164
8. Sparks, D. L. (1997) Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease? Ann. N.Y. Acad. Sci. 826, 128-146
9. Steinberg, D. (1997) Oxidative modification of LDL and atherogenesis. Circulation 95, 1062-1071
10. Stanyer, L., Betteridge, D. J. and Smith, C. C. T. (2002) An investigation into the mechanisms mediating plasma lipoprotein-potentiated β-amyloid fibrillogenesis. FEBS Lett. 518, 72-78
11. Stanyer, L., Betteridge, D. J. and Smith, C. C. T. (2004) Potentiation of β-amyloid polymerisation by low-density lipoprotein enhances the peptide's vasoactivity. Biochim. Biophys. Acta 1670, 147-155
12. Thomas, T., Thomas, G., McLendon, C., Sutton, T. and Mullan, M. (1996) β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168-171
13. Crawford, F., Soto, C., Suo, C. Z. et al. (1998) Alzheimer's β-amyloid vasoactivity: identification of a novel β-amyloid conformational intermediate. FEBS Lett. 436, 445-448
14. Crawford, F., Suo, Z., Fang, C. and Mullan, M. (1998) Characteristics of the in vitro vasoactivity of β-amyloid peptides. Exp. Neurol. 150, 159-168
15. Walsh, D. M., Klyubin, I., Fadeeva, J. et al. (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539
16. Hatch, F. T. and Lees, R. S. (1968) Practical methods for plasma lipoprotein analysis. Adv. Lipid Res. 6, 1-68
17. Wang, C. and Smith, R. L. (1975) Lowry determination of protein in the presence of Triton X-100. Anal. Biochem. 63, 414-417
18. Schuh, J., Fairclough, G. F. and Haschmeyer, R. H. (1978) Oxygen mediated heterogeneity of apo-low-density lipoprotein. Proc. Natl. Acad. Sci. U.S.A. 75, 3173-3177
19. Corongui, F. P. and Banni, S. (1994) Detection of conjugated dienes by second derivative ultraviolet spectrophotometry. Methods Enzymol. 233, 303-310
20. Naiki, H., Higuchi, K., Hosokawa, M. and Takeda, T. (1989) Fluorimetric determination of amyloid fibrils in vitro using the fluorescent dye thioflavin T. Anal. Biochem. 177, 244-249
21. Smith, C. C. T., Stanyer, L. and Betteridge, D. J. (2004) Soluble β-amyloid (Aβ)40 causes attenuation or potentiation of noradrenaline-induced vasoconstriction in rats depending upon the concentration employed. Neurosci. Lett. 367, 129-132
22. Wisniewski, H. M., Wegeil, J., Wang, K. C. and Lech, B. (1992) Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. Acta Neuropathol. 84, 117-127
23. Martel, C. L., Mackic, J. B., McComb, J. G., Ghiso, J. and Zlokovic, B. V. (1996) Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid-β in guinea pigs. Neurosci. Lett. 206, 157-160
24. Su, G. C., Arendash, G. W., Kalaria, R. N., Bjugstad, K. B. and Mullan, M. (1999) Intravascular infusions of soluble β-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res. 818, 105-117
25. Lorenzo, A. and Yankner, B. A. (1996) Amyloid fibril toxicity in Alzheimer's disease and diabetes. Ann. N.Y. Acad. Sci. 777, 89-95
26. Glenner, G. G. and Wong, C. W. (1984) Alzheimer's disease: initial report of the purification and characterisation of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890
27. Masters, C. L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R. N. and Beyreuther, K. (1985) Neuro-fibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4, 2757-2763
28. Yan, S. D., Chen, X., Fu, J. et al. (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691
29. Dhaliwal, B. S. and Steinbrecher, U. P. (1999) Scavenger receptors and oxidised low density lipoproteins. Clin. Chim. Acta 286, 191-205